WO2002000725A3 - G-protein coupled receptor org10 - Google Patents

G-protein coupled receptor org10 Download PDF

Info

Publication number
WO2002000725A3
WO2002000725A3 PCT/EP2001/007018 EP0107018W WO0200725A3 WO 2002000725 A3 WO2002000725 A3 WO 2002000725A3 EP 0107018 W EP0107018 W EP 0107018W WO 0200725 A3 WO0200725 A3 WO 0200725A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
protein coupled
coupled receptor
org10
receptors
Prior art date
Application number
PCT/EP2001/007018
Other languages
French (fr)
Other versions
WO2002000725A2 (en
Inventor
Morag A Grassie
Emma Jane Grant
Johannes Petrus Gerardus Klomp
Original Assignee
Akzo Nobel Nv
Morag A Grassie
Emma Jane Grant
Johannes Petrus Gerardus Klomp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv, Morag A Grassie, Emma Jane Grant, Johannes Petrus Gerardus Klomp filed Critical Akzo Nobel Nv
Priority to EP01960347A priority Critical patent/EP1297139A2/en
Priority to AU2001281862A priority patent/AU2001281862A1/en
Priority to JP2002505847A priority patent/JP2004501629A/en
Priority to US10/312,094 priority patent/US20030162945A1/en
Publication of WO2002000725A2 publication Critical patent/WO2002000725A2/en
Publication of WO2002000725A3 publication Critical patent/WO2002000725A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)

Abstract

The present invention provides a full length cDNA sequence that codes for a G-protein coupled receptor, as well as the complete gene and the encoded protein. The present invention provides a recombinant cell line expressing these receptors at appropriate levels such that novel compounds active at these receptors may be identified for therapeutic use. The receptor sequence described in this invention is a member of a novel GPCR receptor sub-family which has no known endogenous ligand. This cDNA can be used to identify novel compounds active at the receptor for therapeutic use especially in the field of CNS disorders, neurodegeneration or analgesia.
PCT/EP2001/007018 2000-06-26 2001-06-20 G-protein coupled receptor org10 WO2002000725A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01960347A EP1297139A2 (en) 2000-06-26 2001-06-20 G-protein coupled receptor org10
AU2001281862A AU2001281862A1 (en) 2000-06-26 2001-06-20 G-protein coupled receptor org10
JP2002505847A JP2004501629A (en) 2000-06-26 2001-06-20 G-protein coupled receptor ORG10
US10/312,094 US20030162945A1 (en) 2000-06-26 2001-06-29 G- protein coupled receptor org10

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00305379.0 2000-06-26
EP00305379 2000-06-26

Publications (2)

Publication Number Publication Date
WO2002000725A2 WO2002000725A2 (en) 2002-01-03
WO2002000725A3 true WO2002000725A3 (en) 2002-04-11

Family

ID=8173083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007018 WO2002000725A2 (en) 2000-06-26 2001-06-20 G-protein coupled receptor org10

Country Status (4)

Country Link
EP (1) EP1297139A2 (en)
JP (1) JP2004501629A (en)
AU (1) AU2001281862A1 (en)
WO (1) WO2002000725A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031258A2 (en) * 1998-11-20 2000-06-02 Arena Pharmaceuticals, Inc. Human orphan g protein-coupled receptors
WO2000053622A1 (en) * 1999-03-09 2000-09-14 Smithkline Beecham Corporation 7tm receptor (axor23)
WO2001016179A1 (en) * 1999-08-27 2001-03-08 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
EP1094109A2 (en) * 1999-10-21 2001-04-25 Pfizer Limited Human G protein-coupled receptor, PFI-010

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031258A2 (en) * 1998-11-20 2000-06-02 Arena Pharmaceuticals, Inc. Human orphan g protein-coupled receptors
WO2000053622A1 (en) * 1999-03-09 2000-09-14 Smithkline Beecham Corporation 7tm receptor (axor23)
WO2001016179A1 (en) * 1999-08-27 2001-03-08 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
EP1094109A2 (en) * 1999-10-21 2001-04-25 Pfizer Limited Human G protein-coupled receptor, PFI-010

Also Published As

Publication number Publication date
AU2001281862A1 (en) 2002-01-08
EP1297139A2 (en) 2003-04-02
JP2004501629A (en) 2004-01-22
WO2002000725A2 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
WO2006052723A3 (en) G protein coupled receptor agonists and antagonists and methods of use
WO2000031258A3 (en) Human orphan g protein-coupled receptors
WO2002046227A3 (en) Glp-1 fusion proteins
WO2004039951A3 (en) Il-1 receptor based antagonists and methods of making and using
WO2001081408A3 (en) G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
WO2000022131A3 (en) Non-endogenous, constitutively activated human g protein-coupled receptors
WO2001031014A3 (en) G protein-coupled receptors expressed in human brain
WO2003058203A3 (en) Extended glucagon-like peptide-1 analogs
WO2001077172A3 (en) Non-endogenous, constitutively activated known g protein-coupled receptors
HK1085932A1 (en) Degraded agonist antibody
LT2000123A (en) Biphenyl sulfonamides as dual angiotensin endothelin receptor anatgonists
WO2003027246A3 (en) Antagonists
WO2002032374A3 (en) Methods for treating il-18 mediated disorders
WO2005000877A3 (en) Novel melanocortin receptor templates, peptides, and use thereof
WO2002068600A3 (en) Endogenous and non-endogenous versions of human g protein-coupled receptors
WO2003002604A3 (en) G protein coupled receptors and dna sequences thereof
WO2005009358A3 (en) Conformationally constrained parathyroid hormone (pth) analogs
WO2002102839A3 (en) Novel g-protein coupled receptors and dna sequences thereof
WO2003018798A3 (en) G-protein coupled receptor and dna sequences thereof
WO2002000725A3 (en) G-protein coupled receptor org10
AU1177102A (en) Recombinant antibody fragments as autoantibody antagonists
WO2001085791A8 (en) Nucleic acid sequences for novel gpcrs
WO2000050563A3 (en) G protein-coupled receptor resembling galanin receptors
EP1695968A4 (en) The glucagon-like peptide-1 receptor agonists, the preparation and the use of the same
WO2002068585A3 (en) Tip39 polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PL RO RU SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PL RO RU SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001960347

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10312094

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 505847

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001960347

Country of ref document: EP

712F Gb: determination of foreign entitlement (section 12(1)/1977)
WWW Wipo information: withdrawn in national office

Ref document number: 2001960347

Country of ref document: EP